The endocannabinoid anandamide is removed from the synaptic space by a selective transport system, expressed in neurons and astrocytes, that remains molecularly uncharacterized. Here we describe a partly cytosolic variant of the intracellular anandamidedegrading enzyme fatty acid amide hydrolase-1 (FAAH-1), termed FAAH-like anandamide transporter (FLAT), that lacked amidase activity but bound anandamide with low micromolar affinity and facilitated its translocation into cells. Known anandamide transport inhibitors, such as AM404 and OMDM-1, blocked these effects. We also identified a competitive antagonist of the interaction of anandamide with FLAT, the phthalazine derivative ARN272, that prevented anandamide internalization in vitro, interrupted anandamide deactivation in vivo and exerted profound analgesic effects in rodent models of nociceptive and inflammatory pain, which were mediated by CB 1 cannabinoid receptors. The results identify FLAT as a critical molecular component of anandamide transport in neural cells and a potential target for therapeutic drugs.
a r t I C l e S Brain cells release a variety of lipid mediators, which act in close proximity to their site of production to modulate synaptic plasticity and neural development 1 . The reliability of this highly localized form of neural communication depends on the existence of deactivation mechanisms that ensure the rapid termination of lipid-mediated signaling, but few such mechanisms have been discovered so far. Anandamide is an arachidonic acid derivative that regulates ionchannel activity and neurotransmitter release by engaging CB 1 cannabinoid receptors on axon terminals 2 . There is evidence that the intensity and duration of anandamide signaling are controlled by a two-step elimination process in which the substance is first internalized by neurons and astrocytes [3] [4] [5] and then hydrolyzed by the intracellular membrane-bound amidases FAAH-1 and FAAH-2 (refs. [6] [7] [8] . Removal of anandamide from the extracellular space shows several identifying features of a carrier-mediated facilitated diffusion process 4, 9, 10 : (i) it is saturable and has low micromolar affinity for anandamide (apparent Michaelis constant K M , 1.2 µM in rat cortical neurons) 3 ; (ii) it preferentially recognizes anandamide over similar molecules, including the non-cannabinoid FAAH substrates oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) 3, 11 ; (iii) it is inhibited in a competitive and stereoselective manner by substrate mimics 10 ; and (iv) it does not require cellular energy 3, 4 . Inhibitors of anandamide transport, which include the compounds AM404 and OMDM-1 (ref. 10) , increase amounts of this endocannabinoid substance in vivo and produce a spectrum of CB 1mediated responses that only partially overlap with those elicited by FAAH blockade, presumably owing to the different kinetic properties and substrate preferences of the two deactivation mechanisms 10 . These data indicate that carrier-mediated transport may be important for terminating the actions of anandamide and might represent a potential drug target 10 . Nevertheless, the molecular entity (or entities) involved in anandamide translocation is still unknown, and the mechanistic bases of this process remain controversial 5, 12 . Here, we identify a partly cytosolic variant of FAAH-1, termed FLAT, that lacks amidase activity but binds anandamide with low micromolar affinity and confers anandamide transport on cells that are engineered to express it. AM404 and other anandamide transport inhibitors suppress these effects. Moreover, we disclose a small-molecule competitive inhibitor of the interaction of anandamide with FLAT, the compound ARN272, and show that this agent suppresses anandamide translocation in vitro and interrupts anandamide deactivation in vivo.
RESULTS

FLAT is an intracellular anandamide-binding protein
We isolated total RNA from brain and other rat tissues, and amplified products of the Faah gene using reverse transcriptase polymerase chain reaction (RT-PCR). One of the cDNA products obtained was identical to Faah except that it lacked a 204-base-pair segment encoding amino acid residues 9-76 ( Fig. 1a, Supplementary  Fig. 1a-c) . RNase protection assays and Southern blot analyses of reverse transcriptase-generated cDNA confirmed the occurrence of FLAT mRNA in rat brain and liver tissue ( Supplementary  Fig. 1d,e ). Quantitative RT-PCR measurements showed that FLAT was unevenly transcribed in the rat brain, with highest a r t I C l e S amounts in neocortex and hippocampus and lowest in brainstem and hypothalamus ( Supplementary Fig. 1f ). Detectable FLAT mRNA was also found in rat primary astrocytes in cultures, rat neuroblastoma cells and human astrocytoma cells ( Supplementary  Fig. 1c) , which were previously shown to have anandamide transport activity 3, 11, 13 . An antibody raised against the C terminus of FAAH-1 identified in brain cytosolic and membrane fractions obtained from wild-type mice, but not in those obtained from FAAH-1-deficient mice, a band with an apparent molecular weight of 56 kDa, which is consistent with the calculated molecular weight of FLAT (56,008 Da) ( Supplementary  Fig. 1g ). This suggests that FLAT might be a product of the Faah gene generated by alternative splicing at noncanonical sites 14 . The predicted structure of FLAT lacks most of FAAH-1's α1 helix, which spans the lipid bilayer of intracellular membranes, and the entire α2 helix, which flanks the globular body of the protein exposed to the cytosol (Fig. 1b) 15 .
When expressed in HEK-293 cells, FLAT showed no detectable amidase activity toward anandamide or OEA ( Supplementary Fig. 2a,b ), suggesting that the protein is catalytically deficient. Computational studies identified two factors that might contribute to this loss of activity: (i) increased flexibility of regions proximal to the missing α1 and α2 helices, such as the 'α2-interacting loop' (Fig. 1b) , could facilitate access of water to the catalytic site buried in the enzyme's hydrophobic core ( Supplementary Fig. 3 ) 7 ; and (ii) deletion of the α2 helix, which carries a positively charged surface, could lower the electrostatic potential in the region surrounding the catalytic triad component Lys74 (corresponding to Lys142 in FAAH-1) 7 (Supplementary Fig. 4 ). Both factors are expected to impair amidase activity by interrupting the proton transfer from Ser173 (corresponding to catalytic Ser241 in FAAH-1) to neutral Lys74. Though critical for the amidase activity of FAAH-1, Lys142 does not influence the ability of this enzyme to cleave ester substrates 16 . Consistent with those data and the model proposed here, we found that recombinant FLAT effectively hydrolyzed the fatty acyl ester 2-oleoyl-sn-glycerol ( Supplementary Fig. 2c ).
Like FAAH-1, recombinant purified FLAT formed homodimers in aqueous solution ( Supplementary Fig. 5 ). To test whether FLAT also retains the ability to bind anandamide, we expressed the protein fused with glutathione-S-transferase (GST) in E. coli and purified it by affinity chromatography. Saturation binding studies showed that [ 3 H]anandamide associated with FLAT-GST (dissociation constant K d = 2 µM), but not with GST alone (Fig. 2a) . The binding of [ 3 H]anandamide to FLAT was displaced by the anandamide transport inhibitors AM404 and OMDM-1 ( Fig. 2b) , with median inhibitory concentrations (IC 50 ) similar to those required for the inhibition of neuronal [ 3 H]anandamide internalization (IC 50 : AM404, 5.3 µM; OMDM-1, 4.8 µM) 10, 17 . By contrast, the covalent FAAH inhibitor URB597 had no such effect ( Fig. 2b) , likely because the productive interaction of this compound with the Ser241 nucleophile of FAAH-1 requires a fully functional catalytic triad 18 . Collectively, the experiments described above indicate that FLAT lacks amidase activity but binds anandamide with low micromolar affinity.
FLAT facilitates anandamide transport
We detected appreciable amounts of FLAT in cytosol fractions prepared from mouse brain ( Supplementary Fig. 1g ) or transfected HEK-293 cells ( Fig. 2c) and found that the protein could be readily detached from HEK-293 cell membranes by incubation with sodium carbonate (0.1 M) ( Supplementary Fig. 6 ) 19 . These properties, along with the observation that AM404 and OMDM-1 antagonize the binding of [ 3 H]anandamide to FLAT ( Fig. 2b) , suggested a role in anandamide translocation. Such a role was further implied by the reduced [ 3 H]anandamide accumulation observed in cultures of brain neurons obtained from Faah −/− mice ( Supplementary  Fig. 7 ) 20, 21 , which lack both FAAH-1 and FLAT ( Supplementary  Fig. 1g ). We examined therefore whether heterologous expression of FLAT might increase anandamide transport in HEK-293 cells. We incubated control and FLAT-expressing cells for 5 min at 37 °C in a buffer containing [ 3 H]anandamide and measured cell-associated radioactivity after removal of excess tracer 3, 11 . Compared to controls, FLAT-expressing cells had significantly higher [ 15 , which is redrawn in green for illustration purposes. Most of the α1 helix and the entire α2 helix (orange) of FAAH-1 are absent in FLAT. Both FAAH-1 and FLAT contain a membranebinding domain (blue, FLAT residues 343-367) and an α2-interacting loop (red, FLAT residues 187-210), which may interact with the α2 helix and help shield the enzyme's catalytic pocket from water. The membrane model was generated using molecular dynamics simulations of a 1,2-dioleoyl-sn-glycerol-3phosphorylcholine bilayer 39 .
a r t I C l e S accumulation, which (i) was prevented by AM404 (IC 50 = 4 µM) and other transport inhibitors (OMDM-1, UCM707, VDM11), as well as by nonradioactive anandamide (100 µM) ( Fig. 2d, 22 , because the very low amidase activity present in native HEK-293 cells was not increased by FLAT expression ( Supplementary  Fig. 2a,b) . Moreover, treatment with a maximally active concentration of the FAAH inhibitor URB597 (1 µM) or mutation of Ser173 (corresponding to the nucleophile Ser241 in FAAH-1) did not affect [ 3 H]anandamide uptake by FLAT-expressing HEK-293 cells ( Fig. 2e) . URB597 did not affect [ 3 H]anandamide uptake at any of the concentration tested (up to 10 µM: 103 ± 5% of vehicle control (mean ± s.e.m.)).
In addition to internalizing anandamide, the anandamide transport system may also facilitate the release of this lipid mediator from cells 4, 23 . To test whether FLAT contributes to this process, we overexpressed the protein in mouse Neuro-2a cells and measured, by liquid chromatography/mass spectrometry, endogenously produced anandamide in the incubation medium. Consistent with a role in anandamide release, FLAT overexpression was accompanied by a substantial elevation in extracellular anandamide, but not 2-AG or OEA (Supplementary Fig. 8 ). The results suggest that FLAT facilitates anandamide translocation through a mechanism that is selective for anandamide, independent of amidase activity and prevented by known inhibitors of anandamide transport. a r t I C l e S
Discovery of a competitive FLAT inhibitor
To further investigate the functions of FLAT and to differentiate them from those of FAAH-1, we searched for small drug-like molecules that might selectively interfere with FLAT's ability to sequester anandamide. We subjected a virtual library of 4.3 million compounds to a ligand-screening campaign structured in multiple steps of progressively increasing stringency (Supplementary Fig. 9 ). The campaign returned a set of 46 structurally diverse compounds, which we tested for their interaction with FLAT in vitro. One of them, the substituted phthalazine ARN272 (Fig. 3a) , competitively antagonized [ 3 H]anandamide binding to purified FLAT (IC 50 = 1.8 µM; Fig. 3a ) and inhibited [ 3 H]anandamide accumulation in both FLATexpressing HEK-293 cells (IC 50 ≈ 3 µM; Fig. 3b ) and primary cultures of cortical neurons prepared from rats (Fig. 3c) or wild-type mice (Supplementary Fig. 7) . By contrast, ARN272 exerted no effect on the residual [ 3 H]anandamide accumulation observed in cortical neurons of Faah −/− mice (Supplementary Fig. 7) .
FLAT inhibition by ARN272 seemed selective, because the compound had little or no inhibitory activity on several endocannabinoid-metabolizing enzymes, including N-acylphosphatidylethanolamine-selective phospholipase D, diacylglycerol lipase-α, monoacylglycerol lipase and N-acylethanolamide-hydrolyzing acid amidase (Supplementary Fig. 10a-d) . Moreover, ARN272 produced only a weak and incomplete inhibition of rat brain FAAH activity ( Fig. 3d) and was not appreciably hydrolyzed after incubation with recombinant human FAAH-1 (~5% hydrolysis after 24 h at 37 °C). Consistent with these observations, administration of ARN272 in mice (1 mg per kilogram body weight, intraperitoneally (i.p.)) increased plasma anandamide (Fig. 3e) without changing 2-AG, OEA or PEA (Fig. 3f) . The inhibitory effects of ARN272 on anandamide internalization in vitro and anandamide deactivation in vivo, along with the diminished anandamide accumulation observed in Faah −/− mice, suggest that FLAT is important in the membrane translocation of this endocannabinoid transmitter.
ARN272 attenuates nociceptive and inflammatory pain
Anandamide transport inhibitors produce a variety of CB 1 -mediated responses, which include analgesia in animal models of nociceptive and inflammatory pain 24, 25 . We therefore tested whether ARN272 might alleviate pain-related behaviors elicited in mice by intraplantar injection of the chemical irritant formalin. Systemic administration of ARN272 (0.01-1 mg kg −1 , i.p.) caused a dose-dependent reduction of formalin-induced pain behavior (Fig. 4a) . Substantial antinociceptive activity was observed on both the first phase of formalin pain, which involves acute activation of sensory C fibers, and the second phase of formalin pain, in which sensory fiber activity is accompanied by inflammation and central sensitization (Fig. 4a) . We observed similar effects when we injected ARN272 (0.01-3 µg per animal) into the cerebral ventricles (Supplementary Fig. 11 ). The CB 1 antagonist AM251 suppressed the antinociceptive actions of systemic ARN272, whereas the CB 2 antagonist AM630 and the transient receptor potential vanilloid-1 (TRPV-1) antagonist AMG9810 (all administered at 1 mg kg −1 , i.p.) were ineffective (Fig. 4b) . The CB 1 -mediated antinociceptive effects demonstrated by ARN272 in the formalin test are similar to those previously reported for anandamide transport inhibitors such as AM404, OMDM-1 and UCM707 (ref. 24) .
In another set of experiments, we evaluated the ability of ARN272 to alleviate thermal hyperalgesia and paw edema elicited in mice by the proinflammatory polysaccharide carrageenan. Similarly to FAAH inhibitors 26, 27 , ARN272 (0.01-3 mg kg −1 , i.p.) exerted anti-hyperalgesic ( Fig. 4c and Supplementary Fig. 12 ) and anti-inflammatory effects ( Fig. 4d and Supplementary Fig. 13 ). These were suppressed by blockade of CB 1 but not CB 2 or TRPV-1 receptors (Fig. 4e,f and Supplementary Fig. 14) . ARN272 did not evoke any detectable nocifensive response when administered alone into the mouse paw (Supplementary Table 1) , confirming its inability to interact productively with TRPV-1. Finally, ARN272 did not significantly alter the binding of the cannabinoid ligands [ 3 H]CP55940 or [ 3 H]anandamide to rat brain membranes (Supplementary Fig. 10e) . Together, the findings indicate that ARN272 elicits profound analgesic effects in mice, which result from inhibition of anandamide transport.
DISCUSSION
The functional properties of FLAT suggest that this protein is a key molecular component of the anandamide transport system in neural cells and is a potential target for therapeutic drugs. The findings presented here indicate that FLAT selectively binds to and internalizes anandamide and that several known inhibitors of anandamide translocation-AM404, OMDM-1, UCM707 and VDM11 (ref. 10)interfere with these properties. Moreover, our results show that ARN272, a small-molecule inhibitor of the interaction of anandamide with FLAT, suppresses anandamide accumulation by rat brain a r t I C l e S neurons in vitro and reproduces two key effects of transport blockade in vivo: elevation of plasma anandamide, and analgesia in models of nociceptive and inflammatory pain 3 . Consistent with these data and previous reports 3, 20, 21, 23 , deletion of the Faah gene substantially reduced anandamide transport in mouse cortical neurons, whereas acute pharmacological blockade of FAAH activity did not do so.
Although implying that FLAT is important in anandamide transport, our findings do not rule out the possibility that more components of the endocannabinoid transport system remain to be discovered. In this context, we note that FLAT expression did not confer [ 3 H]2-AG or [ 3 H]OEA transport on HEK-293 cells, and administration of the FLAT inhibitor ARN272 did not increase plasma 2-AG or OEA in mice, which indicates that the translocation of these lipid mediators 4,28,29 may be independent of FLAT. Because of its ability to inhibit anandamide deactivation selectively, ARN272 may be useful to differentiate the functions of anandamide from those of other lipid amides that are substrates for FAAH (for example, OEA and PEA).
Multicellular organisms use protein carriers to coordinate the traffic of functionally important lipids and target these biomolecules toward specific cells and subcellular compartments. Two main types of lipidcarrier proteins are used for this task: integral membrane transporters, such as CD36 (ref. 30 ) and PGT 31 , and lipid chaperones, such as aP2 and mal1 (fatty acid-binding proteins 4 and 5, respectively) 32 . For example, membrane-bound CD36 in small intestinal enterocytes captures dietary oleic acid and directs it toward the intracellular biosynthesis of OEA, an important gut hormone 33 . However, cytosolic aP2 in adipocytes encapsulates fatty acids derived from the circulation and partitions them toward appropriate cellular sites for storage or oxidative metabolism 32 . Our experiments suggest that, similarly to a lipid chaperone, FLAT might function by desorbing anandamide from the cell membrane and delivering it to intracellular organelles where FAAH-1 is located 34 (Supplementary Fig. 15 ). It is also possible, though remains to be fully tested, that FLAT might contribute to anandamide release by facilitating the intracellular transfer of this lipophilic molecule from its as-yet-unknown site of biosynthesis to the cell membrane.
Despite its similarities with other lipid chaperones, FLAT appears to be functionally distinct in at least two ways. First, its substrate preference and sensitivity to pharmacological agents distinguish it from other carriers for lipophilic ligands, such as serum albumin and fatty acid-binding proteins, which are known to sequester anandamide [35] [36] [37] [38] . Second, our studies suggest that the capacity of FLAT to ligate anandamide may be based on structural modifications that silence the amidase activity of FAAH-1 without compromising its anandamide-binding function. This mechanism provides an elegant example of phylogenetic parsimony and raises the possibility that other lipid transporters might have evolved following similar principles.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureneuroscience/. 
ONLINE METHODS
FlAT model. The α2 helix (residues 37 to 68) was removed from the crystal structure of FAAH-1-∆TM (PDB 1MT5) 15 and positions 69 to 75 modeled de novo. The cocrystallized ligand and water molecules were removed. Hydrogen atoms and missing heavy atoms were added. Side chains of residues 69-75, zero occupancy side chains and polar hydrogen atoms were assigned the lowest energy conformations. Tautomeric states of histidines and the positions of asparagine and glutamine side chain amidic groups were optimized to improve the hydrogen bond pattern. monte carlo simulations. Conformational analysis of the α2-interacting loop was performed using the Metropolis biased probability Monte Carlo (BPMC) method as implemented in ICM3. 7 (ref. 40) . The initial temperature was set at 600 K. A total of 5 × 10 7 energy evaluations were carried out. The variables sampled during the simulation were the backbone and side chain torsional angles of the loop amino acids. The side chain torsional variables of all the amino acids with at least one heavy atom within 2 Å from the loop were minimized together with the sampled variables before acceptance or rejection according to the Metropolis criterion. molecular dynamics simulations. Molecular dynamics simulations were conducted using the NAMD 2.6 (ref. 41 ) software and the Amber99SB force field 42 . FLAT and FAAH-1-∆TM were solvated in explicit solvent. The dimensions of the simulation box were chosen so to keep a margin of at least 8 Å from the solute in each coordinate direction, and the electro-neutrality of the cell was reached by adding counter-ions. The simulations were performed in the isobaric-isothermal statistical ensemble with periodic boundary conditions. Langevin dynamics was undertaken at the temperature of 300 K with a frictional coefficient of 5 ps −1 at the target pressure of 1 atm. A uniform time-stepping of 2 fs was used. Bonds involving hydrogen atoms were restrained to their reference value. Short-range non-bonded interactions were calculated using a distance cutoff of 10 Å. Long-range electrostatic interactions were considered using the particle mesh Ewald method. The system was thermalized during 150 ps of molecular dynamics while smoothly releasing restraints initially applied on the protein heavy atoms. The system was then allowed to evolve for a total simulated time of 100 ns. electrostatic simulations. The Poisson-Boltzmann equation was solved over a system in which FLAT was modeled as a polarizable solute and the solvent was modeled as a high-dielectric continuum plus an ionic strength of 0.145 M. Electrostatic potential values generated by representative structures of FLAT and FAAH-1-∆TM at the ζ nitrogen site of Lys142 were calculated and compared using DelPhi software 43 . The simulations suggested that the α2 helix brings a positive electrostatic contribution to the lysine site. This contribution is the sum of the mere helix dipolar potential and the overall net charge potential generated by titratable residues borne by the α2 helix. In FLAT, this effect is only partially compensated by the reaction field generated by the solvent that replaces the α2 helix. The pK a shift between the two forms was estimated quantitatively by performing electrostatic calculations according to a conceptual thermodynamic cycle:
where ∆TM represents FAAH-1-∆TM. This calculation provided a positive average pK a shift of about 0.8 pK a units, pointing to an increased probability of having a protonated catalytic lysine in FLAT. Then, to avoid a bias toward known scaffolds, molecules within a Tanimoto distance between 0 and 0.6 (with 0 indicating that two molecules share an identical fingerprint generated according to the Daylight algorithm (Daylight Chemical Information Systems) from any of the five template compounds were discarded. At the end of the prefiltering steps, 122,095 unique molecules were selected. Docking procedure. The boundaries of the binding pocket were calculated using the Pocketome Gaussian Convolution algorithm as implemented in ICM3.7. The three-dimensional models of 122,095 molecules were automatically built and docked at the FLAT binding site according to the ICM3.7 standard docking procedure. This step identified 4,601 compounds that matched the energy criterion of -32 arbitrary score units.
Cluster analysis and visual inspection. The chosen compounds were submitted to an unweighted pair group method with arithmetic mean (UPGMA) chemical clustering procedure. The functional partition was selected at a threshold value of 0.5 Tanimoto distances. This returned 56 unique clusters. Depending on the cluster cardinality, one to three representatives were selected, providing 124 potential FLAT binders. After visual inspection, 53 compounds were selected and 46 that were available from commercial vendors were subjected to testing in vitro. chemicals. Anandamide, AM404, VDM11, UCM707, Win55212 and AMG9810 were purchased from Tocris. λ-Carrageenan, AM251, AM630, PEG 400 and Tween-80 were from Sigma-Aldrich. ARN272 [(4-(5-(4-hydroxyphenyl)-3,4-diaza-bicyclo[4.4.0]deca-1(6),2,4,7,9-pentaen-2-ylamino)-phenyl)phenylamino-methanone] was from Ambinter. ARN272 was purified by liquid chromatography (LC) and its identity was confirmed by mass spectrometry (MS) and 1 FlAT cloning and expression. Rat FLAT mRNA was amplified by PCR using the following primers: forward, 5′-ACCATGGTGCTGAGCGAAGTGTGG ACC-3′; reverse, 5′-TCACGATGGCTGCTTTTGAGGGGT-3′. A rat FLAT amplicon was subcloned into the pCRII vector using the TOPO TA Cloning kit (Invitrogen) and splicing was confirmed by sequencing. Amplicons of rat FAAH-1, FLAT and mutated FLAT-S170G were cloned into a pcDNA3.1 expression vector (Invitrogen) under the control of a human cytomegalovirus promoter. HEK-293 cells were cultured in DMEM supplemented with 10% (vol/vol) FBS and transfected with Lipofectamine 2000 (10 µl, Invitrogen) containing 1 µg of plasmids. Culture media were replaced 18 h after transfection with DMEM containing G418 (0.2 mg ml −1 , Calbiochem). After 4 weeks in culture, surviving clones were isolated and analyzed by western blot to select cell lines stably expressing the transgenes. Ser173 in rat FLAT was mutated to glycine using the GeneTailor mutagenesis system (Invitrogen).
RT-PcR.
RNA was extracted with TRIzol (Invitrogen), and cDNA was synthesized from 1 µg of total RNA. PCR was conducted using the following primers: forward, 5′-CATGGTGCAGTACGAGCTGTGG-3′; reverse, 5′-GGACTGGGGGACATTGGTATG-3′. mRNA expression was determined using glyceraldehyde 3-phosphate dehydrogenase as standard.
Rnase protection assays.
Probes comprising nucleotides 20-309 encoding FAAH-1 and nucleotides 20-220 encoding FLAT were generated by PCR followed by subcloning into pCRII vectors. The constructs were linearized by digestion with BamHI and used as templates for in vitro transcription incorporated with 32 P-dCTP (MP Biomedicals) using RNA polymerase SP6 (Roche). RNase protection assays were performed with an RPA III kit (Applied Biosystems).
Southern blot analyses.
Total RNA was extracted from tissues with TRIzol. cDNA was synthesized from 20 µg of total RNA using SuperscriptII RNase H-reverse transcriptase (Invitrogen). cDNA was digested with BlpI and separated by electrophoresis at 30 V overnight. Southern blots were performed using
